Rapid Build of HIV Related Protective Barriers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

600 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-01

Study Completion Date

2021-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to screen the optimal intervention strategies to rapid establish the protective barriers against HIV-infection by maximally decreasing the viremia among HIV- infected patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection

NCT05043129

HIV Infections Covid19

UNKNOWN

Study on the Antiviral Therapy and Immune Reconstitution of Chinese HIV/AIDS Patients

NCT00872417

Acquired Immune Deficiency Syndrome HIV Infections

UNKNOWN PHASE4

Safety and Immunogenicity of Recombinant HIV Vaccines for HIV/AIDS

NCT01881581

Acquired Immunodeficiency Syndrome

UNKNOWN PHASE1

A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP

NCT04066881

HIV Infections

COMPLETED PHASE2

Immunogenicity and Safety of COVID-19 Vaccine in People Living With HIV

NCT05085145

People Living With HIV COVID-19 Vaccine

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Sexual transmission became the primary route of HIV transmission in China and heterosexual transmission also contributed greatly to HIV epidemic which was mostly reported in South-west rural areas. In past years, Yunnan has experienced powerful campaign of scaling-up the HIV identification as well as antrertroviral therapy.

This study will investigate how to reach the last two of HIV'90-90-90 targets': to provide antiretroviral therapy (ART) for 90% of who diagnosed HIV infection and to achieve viral suppression for 90% of those treated.

The study population consists of participants who received an newly diagnosed HIV infection within the study period. All rerolled participants will be randomized into different study group. In intervention group, medical institutions will provide patients personal involved intervention strategies which guided by frequent viral load detection, and providing of the dosage form of 400 mg EFV in their antiviral therapy.

Main assessment measures are viral suppression rate of HIV-infected patients and treatment coverage .

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Viral Suppression of HIV Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

routine care group

Medical institutions will provide patients routine care according to the national program standard.

Group Type NO_INTERVENTION

No interventions assigned to this group

medicine intervention group

The dosage of 400 mg EFV will be used in the antiviral therapy.

Group Type EXPERIMENTAL

The dosage of 400mg EFV

Intervention Type DRUG

The dosage of 400mg EFV will be used in the antiviral therapy.

consolidated intervention group

Medical institutions will provide personal involved intervention strategies as well as the providing of dosage form of 400 mgEFV in their antiviral therapy.

Group Type EXPERIMENTAL

Personal involved intervention strategies

Intervention Type BEHAVIORAL

Medical institutions will provide personal involved intervention strategies for patients which guided by viral load testing monthly until viral load drop below the detection limit.

The dosage of 400mg EFV

Intervention Type DRUG

The dosage of 400mg EFV will be used in the antiviral therapy.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Personal involved intervention strategies

Medical institutions will provide personal involved intervention strategies for patients which guided by viral load testing monthly until viral load drop below the detection limit.

Intervention Type BEHAVIORAL

The dosage of 400mg EFV

The dosage of 400mg EFV will be used in the antiviral therapy.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HIV-positive participants who received an newly diagnosed HIV infection within the study period
* Having a current residential address inside of pilot site limits
* Eighteen years old or above
* HIV transmission is heterosexual contact